title: Influence of radiation quality on mouse chromosome 2 deletions in radiation-induced acute myeloid leukaemia.
abstract: Leukaemia is the prevailing neoplastic disorder of the hematopoietic system. Epidemiological analyses of the survivors of the Japanese atomic bombings show that exposure to ionising radiation (IR) can cause leukaemia. Although a clear association between radiation exposure and leukaemia development is acknowledged, the underlying mechanisms remain incompletely understood. A hemizygous deletion on mouse chromosome 2 (del2) is a common feature in several mouse strains susceptible to radiation-induced acute myeloid leukaemia (rAML). The deletion is an early event detectable 24h after exposure in bone marrow cells. Ultimately, 15-25% of exposed animals develop AML with 80-90% of cases carrying del2. Molecular mapping of leukaemic cell genomes identified a minimal deleted region (MDR) on chromosome 2 (chr2) in which a tumour suppressor gene, Sfpi1 is located, encoding the transcription factor PU.1, essential in haematopoiesis. The remaining copy of Sfpi1 has a point mutation in the coding sequence for the DNA-binding domain of the protein in 70% of rAML, which alters a single CpG sequence in the codon for arginine residue R235. In order to identify chr2 deletions and Sfpi.1/PU.1 loss, we performed array comparative genomic hybridization (aCGH) on a unique panel of 79rAMLs. Using a custom made CGH array specifically designed for mouse chr2, we analysed at unprecedentedly high resolution (1.4M array- 148bp resolution) the size of the MDR in low LET and high-LET induced rAMLs (32 X-ray- and 47 neutron-induced). Sequencing of Sfpi1/PU.1DNA binding domain identified the presence of R235 point mutations, showing no influence of radiation quality on R235 type or frequency. We identified for the first time rAML cases with complex del2 in a subset of neutron-induced AMLs. This study allowed us to re-define the MDR to a much smaller 5.5Mb region (still including Sfpi1/PU.1), identical regardless of radiation quality.
authors.affiliation: Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire OX11 ORQ, UK.
authors.forename: Natalie
authors.initials: N
authors.lastname: Brown
authors.affiliation: Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire OX11 ORQ, UK.
authors.forename: Rosemary
authors.initials: R
authors.lastname: Finnon
authors.affiliation: Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire OX11 ORQ, UK.
authors.forename: Grainne
authors.initials: G
authors.lastname: Manning
authors.affiliation: Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire OX11 ORQ, UK.
authors.forename: Simon
authors.initials: S
authors.lastname: Bouffler
authors.affiliation: Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, Oxfordshire OX11 ORQ, UK. Electronic address: Christophe.Badie@phe.gov.uk.
authors.forename: Christophe
authors.initials: C
authors.lastname: Badie
mesh_terms: D000818:Animals; D002872:Chromosome Deletion; D033481:Chromosomes, Mammalian / Q000235:genetics / Q000528:radiation effects*; D055028:Comparative Genomic Hybridization; D005260:Female; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics* / Q000662:veterinary; D007953:Leukemia, Radiation-Induced / Q000235:genetics / Q000662:veterinary*; D008297:Male; D051379:Mice; D009502:Neutrons; D017354:Point Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D015534:Trans-Activators / Q000235:genetics*; D014965:X-Rays; D000099232:Proto-Oncogene Protein Spi-1
chemical_list: D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; D000099232:Proto-Oncogene Protein Spi-1
keywords: Chromosome deletion; Mouse model; Myeloid leukemia; Radiation; Sfpi1/PU.1; aCGH